{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:58:18Z","timestamp":1789073898583,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10549-019-05206-y","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T21:05:16Z","timestamp":1553720716000},"page":"649-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Incidence of peripheral edema in patients receiving PI3K\/mTOR\/CDK4\/6 inhibitors for metastatic breast cancer"],"prefix":"10.1007","volume":"175","author":[{"given":"Kayla M.","family":"Daniell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangdi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L.","family":"Brunelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa C.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda E.","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Naoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejan","family":"Juric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Isakoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7306-2398","authenticated-orcid":false,"given":"Alphonse G.","family":"Taghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"key":"5206_CR1","unstructured":"American Cancer Society: Breast Cancer Facts & Figs. 2017\u20132018 (2017) Breast Cancer Facts Fig: 1\u201344. \n                    https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/breast-cancer-facts-and-figures-2017-2018.pdf"},{"issue":"17","key":"5206_CR2","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJMoa050518","volume":"353","author":"D Berry","year":"2005","unstructured":"Berry D, Cronin K, Plevritis S, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353(17):1784\u20131792. \n                    https:\/\/doi.org\/10.1056\/NEJMoa050518","journal-title":"N Engl J Med"},{"issue":"6","key":"5206_CR3","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","volume":"14","author":"T DiSipio","year":"2013","unstructured":"DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500\u2013515. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70076-7","journal-title":"Lancet Oncol"},{"issue":"7","key":"5206_CR4","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1245\/s10434-009-0452-2","volume":"16","author":"RJ Tsai","year":"2009","unstructured":"Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C (2009) The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol 16(7):1959\u20131972. \n                    https:\/\/doi.org\/10.1245\/s10434-009-0452-2","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"5206_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10549-016-4089-0","volume":"162","author":"SF Shaitelman","year":"2016","unstructured":"Shaitelman SF, Chiang Y-J, Griffin KD, DeSnyder SM, Smith BD, Schaverien MV, Woodward WA, Cormier JN (2016) Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat 162(2):201\u2013215. \n                    https:\/\/doi.org\/10.1007\/s10549-016-4089-0","journal-title":"Breast Cancer Res Treat"},{"issue":"32","key":"5206_CR6","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1200\/JCO.2008.16.3725","volume":"26","author":"SA McLaughlin","year":"2008","unstructured":"McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ (2008) Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 26(32):5213\u20135219. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.16.3725","journal-title":"J Clin Oncol"},{"issue":"4","key":"5206_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.21037\/gs.2017.11.04","volume":"7","author":"TC Gillespie","year":"2018","unstructured":"Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG (2018) Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg 7(4):379\u2013403. \n                    https:\/\/doi.org\/10.21037\/gs.2017.11.04","journal-title":"Gland Surg"},{"issue":"3","key":"5206_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ijrobp.2013.11.232","volume":"88","author":"LEG Warren","year":"2014","unstructured":"Warren LEG, Miller CL, Horick N, Skolny MN, Jammallo LS, Sadek BT, Shenouda MN, O\u2019Toole JA, MacDonald SM, Specht MC, Taghian AG (2014) The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys 88(3):565\u2013571. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2013.11.232","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5206_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.breast.2016.04.011","volume":"28","author":"SL Kilbreath","year":"2016","unstructured":"Kilbreath SL, Refshauge KM, Beith JM, Ward LC, Ung OA, Dylke ES, French JR, Yee J, Koelmeyer L, Gaitatzis K (2016) Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast 28:29\u201336. \n                    https:\/\/doi.org\/10.1016\/j.breast.2016.04.011","journal-title":"Breast"},{"issue":"8","key":"5206_CR10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1080\/02841860701403020","volume":"46","author":"S Vignes","year":"2007","unstructured":"Vignes S, Arrault M, Dupuy A (2007) Factors associated with increased breast cancer-related lymphedema volume. Acta Oncol 46(8):1138\u20131142. \n                    https:\/\/doi.org\/10.1080\/02841860701403020","journal-title":"Acta Oncol"},{"issue":"8","key":"5206_CR11","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1245\/s10434-012-2290-x","volume":"19","author":"JLB Bevilacqua","year":"2012","unstructured":"Bevilacqua JLB, Kattan MW, Changhong Y, Koifman S, Mattos IE, Koifman RJ, Bergmann A (2012) Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer. Ann Surg Oncol 19(8):2580\u20132589. \n                    https:\/\/doi.org\/10.1245\/s10434-012-2290-x","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"5206_CR12","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/1097-0142(20010915)92:6<1368::AID-CNCR1459>3.0.CO;2-9","volume":"92","author":"JA Petrek","year":"2001","unstructured":"Petrek JA, Senie RT, Peters M, Rosen PP (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92(6):1368\u20131377. \n                    https:\/\/doi.org\/10.1002\/1097-0142(20010915)92:6%3C1368::AID-CNCR1459%3E3.0.CO;2-9","journal-title":"Cancer"},{"issue":"3","key":"5206_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s10549-011-1667-z","volume":"130","author":"RL Ahmed","year":"2011","unstructured":"Ahmed RL, Schmitz KH, Prizment AE, Folson AR (2011) Risk factors for lymphedema in breast cancer survivors, the Iowa Women\u2019s Health Study. Breast Cancer Res Treat 130(3):981\u2013991. \n                    https:\/\/doi.org\/10.1007\/s10549-011-1667-z","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"5206_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/jpm5030326","volume":"5","author":"MR Fu","year":"2015","unstructured":"Fu MR, Axelrod D, Guth AA, Fletcher J, Qiu JM, Scagliola J, Kleinman R, Ryan CE, Chan N, Haber J (2015) Patterns of obesity and lymph fluid level during the first year of breast cancer treatment: a prospective study. J Pers Med 5(3):326\u2013340. \n                    https:\/\/doi.org\/10.3390\/jpm5030326","journal-title":"J Pers Med"},{"issue":"2","key":"5206_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Uzma Asghar","year":"2015","unstructured":"Uzma Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of taargeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14(2):130\u2013146. \n                    https:\/\/doi.org\/10.1038\/nrd4504","journal-title":"Nat Rev Drug Discov"},{"key":"5206_CR16","unstructured":"Breastcancer.org: Metastatic Breast Cancer (2018). \n                    https:\/\/www.breastcancer.org\/symptoms\/types\/recur_metast"},{"issue":"3","key":"5206_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","volume":"28","author":"B Kaplan","year":"2014","unstructured":"Kaplan B, Qazi Y, Wellen JR (2014) Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev 28(3):126\u2013133. \n                    https:\/\/doi.org\/10.1016\/j.trre.2014.03.002","journal-title":"Transplant Rev"},{"issue":"1","key":"5206_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1078-0432.CCR-16-0134","volume":"23","author":"I Mayer","year":"2017","unstructured":"Mayer I, Abramson V, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC6, Winer Arteaga E CL (2017) A phase Ib study of Alpelisib (BYL719), a PI3K\u03b1-specific inhibitor, with letrozole in ER+\/HER2\u2013 metastatic breast cancer. Clin Cancer Res 23(1):23\u201334. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0134","journal-title":"Clin Cancer Res"},{"issue":"22","key":"5206_CR19","doi-asserted-by":"publisher","first-page":"10208","DOI":"10.1073\/pnas.0907011107","volume":"107","author":"S Loi","year":"2010","unstructured":"Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor\u2013positive breast cancer. Proc Natl Acad Sci USA 107(22):10208\u201310213. \n                    https:\/\/doi.org\/10.1073\/pnas.0907011107","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"5206_CR20","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","volume":"68","author":"K Stemke-Hale","year":"2008","unstructured":"Stemke-Hale K, Gonzalez-Angulo A, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084\u20136091. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6854","journal-title":"Cancer Res"},{"issue":"6","key":"5206_CR21","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/j.1365-2133.2009.09098.x","volume":"160","author":"N Desai","year":"2009","unstructured":"Desai N, Heenan S, Mortimer PS (2009) Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism. BR J Dermatol 160(6):1322\u20131326. \n                    https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09098.x","journal-title":"BR J Dermatol"},{"key":"5206_CR22","unstructured":"United Stated Food and Drug Administration (2017) Highlights of prescribing information for KISQALI\u00ae (ribociclib). \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209092s000lbl.pdf"},{"issue":"35","key":"5206_CR23","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1200\/JCO.2017.73.7494","volume":"35","author":"MS Asdourian","year":"2017","unstructured":"Asdourian MS, Swaroop MN, Sayegh HE, Brunelle CL, Mina AI, Zheng H, Skolny MN, Taghian AG (2017) Association between precautionary behaviors and breast cancer-related lymphedema in patients undergoing bilateral surgery. J Clin Oncol 35(35):3934\u20133941. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.73.7494","journal-title":"J Clin Oncol"},{"issue":"3","key":"5206_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.critrevonc.2014.06.004","volume":"92","author":"NR Taghian","year":"2014","unstructured":"Taghian NR, Miller CL, Jammallo LS, O\u2019Toole J, Skolny MN (2014) Lymphedema following breast cancer treatment and impact on quality of life: a review. Crit Rev Oncol Hematol 92(3):227\u2013234. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2014.06.004","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"5206_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijrobp.2018.08.036","volume":"103","author":"SG McDuff","year":"2018","unstructured":"McDuff SG, Mina AI, Brunelle CL, Salama L, Warren LEG, Abouegylah M, Swaroop M, Skolny MN, Asdourian M, Gillespie T, Daniell K, Sayegh HE, Naoum GE, Zheng H, Taghian AG (2018) Timing of lymphedema after treatment for breast cancer: when are patients most at risk? Int J Radiat Oncol Biol Phys 103(1):62\u201370. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2018.08.036","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"5206_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/jpm5020153","volume":"5","author":"C Brunelle","year":"2015","unstructured":"Brunelle C, Skolny M, Ferguson C, Swaroop M, O\u2019Toole J, Taghian AG (2015) Establishing and sustaining a prospective screening program for breast cancer-related lymphedema at the Massachusetts General Hospital: lessons learned. J Pers Med 5(2):153\u2013164. \n                    https:\/\/doi.org\/10.3390\/jpm5020153","journal-title":"J Pers Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05206-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:27:07Z","timestamp":1585182427000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05206-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5206"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05206-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"11 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Aditya Bardia serves as a consultant for Genentech\/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Spectrum Pharma, and Taiho Pharmeceutical. Aditya Bardia reports institutional grants from Genentech\/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Mersana, and Innocrin, as well as personal funding from Biothernostics. Steven J. Isakoff serves as a consultant for Myriad, Puma, Immunomedics, and Mylan, and reports funding from Genentech, Pharmamar, Abbvie, OncoPep, Merck, AstraZeneca. Dejan Juric serves as a consultant for Novartis, Genentech, Eisai, Ipsen, and EMD Serono. Dejan Juric reports grants from Novartis, Genentech, Eisai, EMD Serono, Takeda, Celgene, and Placon Therpaeutics, as well as personal funding from Novartis, Genentech, Eisai, Ipsen, and EMD Serono. The remaining authors have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}